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Agricultural industry uses pesticides to optimize food production for the growing human
population. A major issue for crops is fungal phytopathogens, which are treated mainly
with azole fungicides. Azoles are also the main medical treatment in the management
of Aspergillus diseases caused by ubiquitous fungi, such as Aspergillus fumigatus.
However, epidemiological research demonstrated an increasing prevalence of azole-
resistant strains in A. fumigatus. The main resistance mechanism is a combination of
alterations in the gene cyp51A (TR34/L98H). Surprisingly, this mutation is not only found
in patients receiving long-term azole therapy for chronic aspergillosis but also in azole
naïve patients. This suggests an environmental route of resistance through the exposure
of azole fungicides in agriculture. In this review, we report data from several studies that
strongly suggest that agricultural azoles are responsible for medical treatment failure in
azole-naïve patients in clinical settings.
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INTRODUCTION
Agriculture undergoes many challenges comprising pests, diseases and abiotic stresses, which
drastically decrease crop yield (Ricroch et al., 2016). This contributes to important losses to farmers
and threatens global food production capacity. A wide range of viral, fungal and bacterial plant
pathogens has been known to contribute for these losses. As an example, Cassava Mosaic and
Brown Streak virus diseases affect food crops in Africa (Food and Agriculture Organization, 2016)
while plant fungal pathogens are responsible for numerous diseases including septoria leaf blotch,
powdery mildews and rusts (Price et al., 2015).
For the last centuries, chemical industries have provided solutions to deal with plant infections
and lower crop losses. The development of antiviral, antibiotics and antifungals has allowed
overcoming the effect of phytopathogens but may have considerable negative impact on the
environment, mainly with regard to the contamination of surface water and groundwater (Azevedo
et al., 2015). Focusing on fungal pathogens, there are a number of antimycotic compounds available
to control the spread of these pathogens. However, it is azole antifungals that are the preferred
treatment owing to their effectiveness against a broad range of fungi (Price et al., 2015). In addition
to controlling the spread of agricultural fungal pathogens, antifungal agents of the azole class play
an important role in the management of human fungal diseases (Snelders et al., 2012).
Among fungal pathogens, many are both present in the environment and in clinic. In
this review, we will focus on Aspergilli, especially, Aspergillus fumigatus, a saprophytic fungus,
developing on decaying vegetation, in soil, and producing volatile conidia (spores) carried in
the air. Such spores are constantly inhaled by humans and in certain conditions could be the
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cause of one of the most frequent human fungal diseases,
aspergillosis which includes allergic, chronic and invasive
aspergillosis (Klich, 2007). In clinic, long-term azole therapy
of aspergillosis led to the emergence of azole resistance in
A. fumigatus over the last decades (Hagiwara et al., 2016).
Surprisingly, azole resistance has also emerged in azole-naive
patients. This observation may be explained by a second route
of resistance development through environmental exposure of
A. fumigatus to azole fungicides used in the field. This leads to
our main question: «Does the massive use of azoles in agricultural
practice lead to antifungal resistance among human pathogens,
impairing medical treatment?».
To address this problem, this review was organized according
to the following topics: In the first part, we will discuss the use of
different azoles in agricultural settings and their mode of action
against plant fungal pathogens. Secondly, we will focus on the
clinical use of azoles to treat patients affected with A. fumigatus,
and finally we will present some studies in favor of a link between
azole resistance due to antifungal use in agriculture and its side
effects on human health.
USE OF AZOLE FUNGICIDES IN
AGRICULTURE
Fungal infections were fought with natural fungicides until the
middle of the 20th century when synthetic fungicides were
introduced. The treatments used from the 17th century, were
mainly mixtures of natural elements or compounds used to
overcome blights, bunts or mildews. Arsenic, brine and copper
sulfate were treatments for different cereal seeds. Copper sulfate
is still used as the main component of Bordeaux mixture, which
is a preventive treatment against mildews in vines, tomatoes, and
potatoes (Morton and Staub, 2008).
In the 1940s, chemically synthesized compounds, like
dithiocarbamates, were released onto the market. They presented
a higher efficiency than earlier compounds, which required up
to 20 kg/ha to be efficient. Effectively, the dithiocarbamates
along with phtalimides, fentins and benzimidazoles were used in
quantities ranging from 1.5 to up to 3 kg per hectare (Morton and
Staub, 2008). However, benzimidazoles were extensively used and
resistance was reported in multiple fungi after only 3–4 seasons of
spraying (Russell, 1995).
Azole, a second generation of chemical antifungals was
introduced in the 1970s. Azoles are unsaturated aromatic
molecules containing at least one nitrogen atom. Today, they are
the most used antifungals because of their high efficiency and
broad spectrum activity (Price et al., 2015) (Table 1). The current
use rates for many triazoles, which are the largest class of azole
antifungals used nowadays, are below/or around 100 g/ha of plant
surface (Morton and Staub, 2008; Azevedo et al., 2015).
Azole antifungals are part of the Sterol Biosynthesis Inhibitors
(SBI) (Azevedo et al., 2015). They affect the same target
in fungal cells. The lanosterol 14α-demethylase (also known
as ERG11) or CYP51A in A. fumigatus is a P450 enzyme
family member. It is an important enzyme, which regulates
ergosterol biosynthetic pathway. Ergosterol is an essential
component that ensures the permeability and fluidity of
the cell membrane (Price et al., 2015). The drug binds
to the enzyme, forming a catalytically inactive complex.
Loss of activity of CYP51A causes interruption of ergosterol
synthesis and a toxic high rate of demethylated lanosterol
in the cell (Price et al., 2015). The effect of the drug
results in a disrupted cell transport and membrane structure.
Fungicides, unlike their name might suggest may only be
fungistatic, as they do not kill fungal cells (Price et al.,
2015). For Aspergilli, their fungicidal effect was shown to be
species and strain dependent. Resistance issues reported in
agriculture have been addressed either by increasing the doses
of fungicides sprayed, or by mixing different fungicide types
(Russell, 1995). Emergence of resistance is not systematically
obtained after antifungal drug exposure as shown by the
work of Kano et al. (2015) who sprayed fields twice a
year with tetraconazole. Lack of antifungal resistance may
be due to the low frequency of azole field treatment or
the use of only one type of azole drug (tetraconazole) as
suggested also by the authors in contrast to real agricultural
practice.
In conclusion, the broad treatment of crops with azoles leads
to an exposure of all fungi present in the field. Aspergilli are
therefore exposed to the fungicide in the environment, leading to
resistance issues that might have consequences on human health
(Snelders et al., 2009).
USE OF AZOLES IN CLINIC AND
RESISTANCE DEVELOPMENT THROUGH
PATIENT EXPOSURE
In clinic, the increasing number of fungal infections causes a
high rate of morbidity and mortality in immunocompromised
patients (Hagiwara et al., 2016). This includes patients with
hematological malignancy, pulmonary diseases, solid-organ or
hematopoietic stem cell transplantation, and patients treated
with corticosteroids (Verweij et al., 2009). Common fungal
infections like chronic or acute invasive aspergillosis, the
allergic bronchopulmonary aspergillosis, and aspergilloma
are caused by Aspergillus (Snelders et al., 2012). Patients
develop these infections by inhaling airborne Aspergillus spp.
conidia, which are normally eliminated by the immune system
but can cause invasive diseases in immunocompromised
individuals. Approximately 30 species of Aspergillus spp. are
involved in Aspergillus spp. infections, but the most frequent
species is Aspergillus fumigatus (A. fumigatus) (Lelièvre et al.,
2013).
To prevent and treat Aspergillar infections, four classes of
antifungal drugs are used: pyrimidine, echinocandin, polyene,
and azoles (Hagiwara et al., 2016). Azoles are major agents
in the treatment and prophylaxis of aspergillosis (Lelièvre
et al., 2013; Hagiwara et al., 2016). Itraconazole, voriconazole
and posaconazole are the most widely used azole antifungal
drugs. Voriconazole is prescribed for the primary treatment
of aspergillosis while posaconazole and itraconazole cause a
reduction of invasive fungal infections in neutropenic patients
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TABLE 1 | Different azole compounds (mainly triazoles) released on the market in
the early 1970s to 2000s.
Year Common name of
compounds
Treatment†
1973 Triadimefon
Imazalil (imidazole)
Broad
Post-harvest and seed
1977 Triadimenol
Prochloraz (imidazole)
Seed treatment
Cereal fungicide
1979 Propiconazole, Bitertanol Broad
1982 Triflumizole Broad
1983 Flutriafol, Diniconazole,
Flusilazole
Broad
1986 Hexaconazole,
Cyproconazole,
Tebuconazole∗
Broad
Broad/foliar and seed
1988 Difenoconazole,
Tetraconazole
Broad/foliar and seed
1990 Epoxiconazole∗ Broad/cereals
1992 Metconazole,
Fluquinconazole,
Triticonazole
Broad
Broad, foliar and seed
2002 Prothioconazole∗ Broad
†The third column shows the use of the different antifungals (Morton and Staub,
2008). ∗Prothioconazole, epoxiconazole and tebuconazole are the most used
antifungals in the United Kingdom, Netherlands, and Denmark (Kleinhauf et al.,
2013).
with acute myeloid leukemia and myelodysplastic syndrome
(Verweij et al., 2009).
The increasing use of azoles in the management of Aspergillus
diseases led to resistances. Resistance is confined to the individual
and no transmission between patients has been reported. Azole-
resistant A. fumigatus strains were first reported in the late
1990s in patients from the United States who had received long-
term itraconazole therapy (Lelièvre et al., 2013). Since then,
many cases of resistant strains were discovered in Europe and
elsewhere, especially in the Netherlands and in the UK where
the prevalence reached 6 and 5%, respectively (Lelièvre et al.,
2013). These resistances are especially found in patients who
received azole drug for a long period to treat chronic aspergillosis.
Azole-resistant isolates are now identified in Norway, Spain,
Belgium, Denmark, France, Germany, India, Iran, Portugal,
Brazil, the Czech Republic, Turkey, Japan, Kuwait, Taiwan,
Australia and China (Rivero-Menedez et al., 2016; Garcia-Rubio
et al., 2017).
Mutation in the cyp51A Gene
The fungus A. fumigatus and the other agricultural fungal
pathogens share the same mechanisms of azole resistance (Price
et al., 2015). This includes several mutations in the cyp51A
gene. These mutations are responsible for substitutions causing
a structural modification of the CYP51A enzyme. This leads
to an alteration in azole’s affinity for the enzyme causing azole
tolerance (Figure 1). Single amino acid substitutions like G54,
P216, F219, M220, and G448 in the CYP51A protein lead to
azole tolerance as shown in Figure 1A (Hagiwara et al., 2016).
These resistance mutations appear in patients with aspergilloma
or other Aspergillus cavities that received long-term azole therapy.
Overexpression of cyp51A
In addition to these point mutations, changes in the promoter
region of the cyp51A gene by the insertion of tandem repeats
or transposable elements lead to an overexpression of CYP51A
(Figure 1B). Indeed, the 34 base-pair tandem repeat (TR34)
which is always found together with a lysine to histidine
substitution at codon 98 (TR34/L98H) induces an up to eightfold
increase of the normal expression of CYP51A (Lelièvre et al.,
2013). It has been hypothesized that the increase of mRNA
levels correlates with the augmentation in cellular CYP51A levels
causing a reduction in azole sensitivity (Price et al., 2015).
Efflux Transporters
Even though CYP51A is the main target of azole compounds,
other enzymes are capable of causing resistance. Eﬄux pumps,
including ATP-binding cassette (ABC) transporters and major
facilitator superfamily (MFS) transporters are necessary in
eukaryotic organisms to remove toxins out of the cell (Jasinski
et al., 2003). Therefore, overexpression of these genes leads
to resistance against azole as the intracellular concentration of
the fungicide decreases (Figure 1C). The fungus A. fumigatus
contains at least 49 genes encoding the ABC transporters.
Among them, it has been shown that 12 genes present a high
homology with S. cerevisiae PDR5 and PDR15 proteins that
are involved in azole resistance too (Hagiwara et al., 2016).
The Cdr1B eﬄux transporter, a member of PDR subfamily,
was shown to be overexpressed in azole-resistant isolates. The
deletion of cdr1B gene in a resistant strain results in increased
sensitivity to itraconazole (Hagiwara et al., 2016). This means
that Cdr1B is primordial for azole resistance in A. fumigatus
(Hagiwara et al., 2016). Recently, it has been demonstrated
that deletion mutants of two other distinct ABC transporters
(AtrF, AtrI) and a major facilitator superfamily transporter
(MdrA) also showed sensitivity to azole drugs (Meneau et al.,
2016).
LINK BETWEEN AZOLE RESISTANCE IN
AGRICULTURE AND CLINIC
Surprisingly, resistance to azoles is confined not only to patients
undergoing azole therapy, but also in many azole naïve patients,
with no known prior exposure to azole drugs (Snelders et al.,
2009). As inhalation of airborne Aspergillus spores is the
common route of infection for Aspergillus diseases, it has been
hypothesized that the resistance could have been acquired from
a common environmental source. For example, if azole-resistant
A. fumigatus is present in our environment, patients could inhale
resistant spores and subsequently develop azole-resistant diseases
(Snelders et al., 2009).
Azoles are found to be actively persistent for several months
in many ecological niches such as agricultural soil and aquatic
environments. As reviewed above, azoles are commonly used in
agriculture as fungicides and also for the preservation of a variety
of materials such as wood. Hence, it was hypothesized that the
fungal exposure to azole compounds in the environment results
in a cross-resistance to medical triazoles (Chowdhary et al., 2013).
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FIGURE 1 | The three mechanisms of resistance to azole drugs. (A) Presence of mutations responsible for substitution causing structural modifications of CYP51A
enzyme leading to a reduced azole affinity. (B) Overexpression of cyp51A gene due to a 34-bp insertion in its promoter region combined with a substitution at codon
98 of leucine to histidine (TR34/L98H) causing an increase in cellular CYP51A level. (C) Overexpression of the genes coding for efflux transporter causing a reduced
intracellular accumulation of azole drug.
To validate this hypothesis, two studies sampled azole resistant
A. fumigatus strains from patients with previous exposure
to azoles and from the environment (flowerbeds, compost,
leaves, plant seeds, soil samples of tea, paddy fields, hospital
surroundings, and aerial samples of hospitals) (Chowdhary
et al., 2013; Verweij et al., 2016) and studied the different
mechanisms of resistance. Surprisingly, a combination of
alterations previously described in patients, were found not only
in clinical samples but also in the environmental isolates. This
includes essentially mutations in the cyp51A gene (TR34/L98H,
G448S and TR46/Y121F/T289A). In addition, a very recent
study, clearly highlighted that an acquisition of mutation in
the azole target by the environmental strains leads to cross
resistance between the azole antifungals in the environment and
the clinic (Ren et al., 2017). Among 144 soil samples treated
with many azoles (epoxiconazole, tebuconazole, propiconazole,
hexaconazole, metconazole), Ren et al. found that 5.8% of
the analyzed samples were resistant to medical azoles (Ren
et al., 2017). Two samples were resistant to voriconazole with
most frequent mutations found in the environmental samples
(TR46/Y121F/T289A). One sample was resistant to itraconazole
with mutation TR34/L98H/S297T/F495I.
TR34/L98H was the most common mutation in both
environmental and clinical samples (Rivero-Menedez et al., 2016;
Verweij et al., 2016). All A. fumigatus isolates with this mutation
showed cross-resistance to medical and agricultural triazoles.
Docking studies revealed that both medical and agricultural
triazoles have similar molecular structures and adopt similar
conformations (Chowdhary et al., 2013). TR34/L98H mechanism
was found to be widespread in The Netherlands and is also
found in other European countries, the Middle East, Asia, Africa,
Australia and, most recently, North and South America. A wide
range of cyp51A mutations were reported in both clinical and
environmental isolates in Austria, Belgium, Denmark, France,
Germany, Greece, Italy, The Netherlands, Poland, Portugal,
Romania, Spain, Sweden, Turkey and the United Kingdom
(Rivero-Menedez et al., 2016). Recently, azole resistance has also
been found in Norway, Iran, Brazil, the Czech Republic, Japan,
Kuwait and Taiwan (Garcia-Rubio et al., 2017).
The following studies were done to gain insights into
the origin and spread of this resistance. Genotyping of
epidemiologically and geographically unrelated strains showed
a lower genetic diversity among isolates harboring TR34/L98H
and TR46/Y121F/T289A compared to wild-type isolates, which
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FIGURE 2 | The environmental and clinical routes of azole resistance development. (A) The exposure of A. fumigatus to azole compounds in agriculture may create
mutations in conidia inducing a resistant phenotype. (B) Azole naive patient becomes ill upon inhalation of airborne resistant and sensitive A. fumigatus strains. (C)
The azole naive patient is treated with medical triazoles creating a persistent pressure of azole leading to the selection of resistant strains. (D) Patients infected by
inhaling sensitive A. fumigatus molds receive long-term azole therapy. (E) A small proportion of patient who received long-term azole therapy without developing
resistant A. fumigatus strains (black arrow). (F) Patients with A. fumigatus resistant strains that have developed through long-term azole therapy (blue arrow) or by
the use of azole in agriculture (green arrow). This induces a failure in the management of Aspergillus diseases. Adapted from Verweij et al. (2009).
suggests that each mutation might have originated from a
common ancestor genotype (Verweij et al., 2016). The azole-
resistant isolates from clinical and environmental samples
exhibited identical phenotype and mechanism of resistance.
Also, microsatellite typing of the isolates showed that the
environmental and clinical azole resistant isolates clustered
together, indicating genetic relatedness, also suggesting the
possibility for a common ancestor (Snelders et al., 2009).
Even if novel point mutations like G54 and M220 were found
exclusively in clinical samples (Rivero-Menedez et al., 2016)
several studies provide evidence that (i) mutations acquired in the
fields confere resistance against agricultural azole but also against
clinical azoles, and (ii) patients with invasive aspergillosis due to
azole-resistant A. fumigatus might acquire the fungus from the
environment.
CONCLUSION AND OUTLOOK
Azole resistance in A. fumigatus develops either during treatment
in the clinic or following intensive agricultural practice as
summarized in Figure 2. The environmental route of resistance
development has been reported since 2007 and is rapidly
appearing worldwide. Even though the highest rates of triazole
resistance have been described in Europe, several cases have been
reported in every continent, and new resistance mechanisms are
being described (Rivero-Menedez et al., 2016), which is highly
problematic for agriculture. Simply prohibiting the use of the
fungicides is not feasible, as this might result in crop disease
epidemics and subsequent food shortages and economic losses.
Hence, there is a necessity to change the practice in the field.
These could include prudent and restricted use of fungicides in
terms of rotation of products, doses and periods of application.
In those cases where resistance to treatment is observed, either
the dosage can be increased or alternative fungicides can be used.
There is also a further need for surveillance, collection
of precise information and extensive programs of resistance
monitoring into the agricultural field to investigate the size
of the emerging problem of azole resistance. Research at
epidemiological level could indicate the geographic variations in
the occurrence of resistance and would facilitate identification
of the regions with high incidence of resistance (SCCNFP,
2003). Furthermore, research at the laboratory level should
aim at understanding the conditions under which resistance
mechanisms develop in the environment and which Aspergillus
morphotype is most prone to develop mechanisms of resistance
(Snelders et al., 2012).
Additionally, the emerging resistances become a threat to
millions of people across the globe because the same resistant
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strains of A. fumigatus observed in the environment are also
found in the clinic. Due to the fact that resistance is associated
with treatment failure, it is necessary to optimize agricultural
practices. In parallel, new, safe and effective classes of antifungals
and compounds that inhibit the resistance mechanisms in fungi
have to be developed in both agriculture and clinic. Modification,
combination, and repurposing of current antifungals and other
FDA-approved drugs and seeking out new sources of antifungal
agents could serve as potential antifungal leads (Ngo et al.,
2016).
Another issue of the extensive use of azoles in agriculture
could be the emergence of resistance in non-environmental
fungi. Non-ubiquitous fungi present in the human flora such
as Candida spp., are constantly in contact with environmental
azoles.
Indeed, this contact occurs inside the body by ingestion of
azole-contaminated food, or by interaction with insects or even
by inhaling recently sprayed azoles on crops. However, this
hypothesis requires further investigations.
Resistance issues are not only confined to fungi, but also
to viral and bacterial pathogens. Finding new drugs and ways
to control microbial pathogens as well as adapting the current
strategies is a major concern for human health.
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